Skip to main content
Journal cover image

Feasibility and toxicity of hypofractionated image guided radiation therapy for large volume limited metastatic disease.

Publication ,  Journal Article
Corbin, KS; Ranck, MC; Hasselle, MD; Golden, DW; Partouche, J; Wu, T; Chmura, SJ; Weichselbaum, RR; Salama, JK
Published in: Pract Radiat Oncol
2013

PURPOSE: Hypofractionated image guided radiation therapy (HIGRT) is increasingly used for limited metastases. Reported studies have mostly treated small volume tumors. Here, we report the toxicity and oncologic outcomes following treatment of large volume metastases. METHODS AND MATERIALS: HIGRT patients treated from October 2005 to March 2010 were reviewed. Gross tumor volumes (GTV) and planning target volumes (PTV) were obtained from planning software. A metastasis was considered large volume if the treated PTV exceeded 50 cc. Patients were treated with either 10-fraction (4-5 Gy per fraction) or 3-5 fraction (8-14 Gy per fraction) regimens. Toxicity was obtained from both prospectively collected databases and retrospectively from patient charts. RESULTS: Sixty-four patients with 93 treated lesions >50 cc were identified. The median GTV and PTV volumes were 41 and 119 cc, respectively. The median number of treated large volume lesions was 1, and a maximum of 3 large volume lesions were treated in a single patient. Primary malignancies included non-small cell lung cancer, renal cell, colorectal, breast, bladder, pituitary, small cell lung cancer, sarcoma, head-and-neck cancer, and hepatocellular cancer. Treated sites included lung (n = 33), regional lymph nodes (n = 20), bone (n = 17), adrenal (n = 9), and liver (n = 6). The most frequently used treatment regimen was 50 Gy in 5 Gy fractions. The median follow-up was 27 months for surviving patients. Treated lesion control was 78%. Low rates of acute and late grade 3 or higher toxicity were reported, with 3 and 5 patients experiencing each, respectively. CONCLUSIONS: HIGRT to large volume oligometastatic disease is tolerable and feasible with promising tumor control. Local radiation therapy should be considered in patients with large volume, limited metastatic disease.

Duke Scholars

Published In

Pract Radiat Oncol

DOI

EISSN

1879-8519

Publication Date

2013

Volume

3

Issue

4

Start / End Page

316 / 322

Location

United States

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Corbin, K. S., Ranck, M. C., Hasselle, M. D., Golden, D. W., Partouche, J., Wu, T., … Salama, J. K. (2013). Feasibility and toxicity of hypofractionated image guided radiation therapy for large volume limited metastatic disease. Pract Radiat Oncol, 3(4), 316–322. https://doi.org/10.1016/j.prro.2012.08.006
Corbin, Kimberly S., Mark C. Ranck, Michael D. Hasselle, Daniel W. Golden, Julien Partouche, Tianming Wu, Steven J. Chmura, Ralph R. Weichselbaum, and Joseph K. Salama. “Feasibility and toxicity of hypofractionated image guided radiation therapy for large volume limited metastatic disease.Pract Radiat Oncol 3, no. 4 (2013): 316–22. https://doi.org/10.1016/j.prro.2012.08.006.
Corbin KS, Ranck MC, Hasselle MD, Golden DW, Partouche J, Wu T, et al. Feasibility and toxicity of hypofractionated image guided radiation therapy for large volume limited metastatic disease. Pract Radiat Oncol. 2013;3(4):316–22.
Corbin, Kimberly S., et al. “Feasibility and toxicity of hypofractionated image guided radiation therapy for large volume limited metastatic disease.Pract Radiat Oncol, vol. 3, no. 4, 2013, pp. 316–22. Pubmed, doi:10.1016/j.prro.2012.08.006.
Corbin KS, Ranck MC, Hasselle MD, Golden DW, Partouche J, Wu T, Chmura SJ, Weichselbaum RR, Salama JK. Feasibility and toxicity of hypofractionated image guided radiation therapy for large volume limited metastatic disease. Pract Radiat Oncol. 2013;3(4):316–322.
Journal cover image

Published In

Pract Radiat Oncol

DOI

EISSN

1879-8519

Publication Date

2013

Volume

3

Issue

4

Start / End Page

316 / 322

Location

United States

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences